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Abstract
 
The CD28 family molecules, CD28, and inducible costimulator (ICOS) all provide positive
costimulatory signals. However, unlike CD28, ICOS does not costimulate IL-2 secretion.
The YMNM motif that exists in the CD28 cytoplasmic domain is a known binding site for
phosphatidylinositol 3-kinase (PI3-K) and Grb2. ICOS possesses the YMFM motif in the
corresponding region of CD28 that binds PI3-K but not Grb2. We postulated that the reason
that ICOS does not have the ability to induce IL-2 production is because it fails to recruit
Grb2. To verify this hypothesis, we generated a mutant ICOS gene that contains the CD28
YMNM motif and measured IL-2 promoter activation after ICOS ligation. The results indicated
that ICOS became competent to activate the IL-2 promoter by this single alteration. Further
analysis demonstrated that Grb2 binding to ICOS was sufficient to activate the NFAT/AP-1 site
in the IL-2 promoter and that the cytoplasmic domain of CD28 outside of the YMNM motif is
required for activation of the CD28RE/AP-1 and NF-
 
 
 
B sites. Together, these observations lead
us to believe that the difference of a single amino acid, which affects Grb2 binding ability, may
define a functional difference between the CD28- and ICOS-mediated costimulatory signals.
Key words: Grb2 • Phosphatidylinositol 3-kinase • NFAT • AP-1 • NF-
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Introduction
 
The activation of naive T cells requires two signals from
the APCs. First, an antigen-specific signal is triggered by
the binding of the TCR to the peptide–MHC complex.
Second, antigen-nonspecific signals are initiated through a
set of costimulatory receptors. Among various costimulatory
receptors, CD28 family molecules, CD28, and CTLA-4
play a pivotal role in T cell–mediated immune responses
(1). We initially identified a novel adhesion molecule
derived from a rat thymoma and designated it as activa-
tion-inducible lymphocyte immunomodulatory molecule
(AILIM; reference 2). Later, it was determined that AILIM
is a rat homologue of the previously reported third member
of the CD28 family gene, inducible costimulator (ICOS;
reference 3).
ICOS ligation has been shown to enhance TCR-mediated
T cell proliferation, indicating that ICOS provides CD28-like
positive costimulatory signals to T cells. The fact that ICOS-
mediated costimulation increases secretion of IL-4, IL-5,
IL-10, IFN-
 
 
 
, and TNF-
 
 
 
 suggests that ICOS functions
primarily to induce T cell effector function (4–6). The
dramatic blocking effects of the ICOS signal with ICOS-Ig
or anti-ICOS antibody and the apparent phenotype of
ICOS-deficient mice in various immune responses all support
the hypothesis that ICOS-mediated costimulation plays a
critical role in T cell–mediated immune responses (5, 7–11).
Recently accumulated data indicates that ICOS performs
a distinct costimulatory function when compared with
CD28 in various immune responses. For example, we have
shown that whereas the blockade of CD28 signaling with
anti-B7 antibody completely abrogates both Th1-driven acute
GVHD and Th2-driven chronic GVHD, the administration
of neutralizing anti-AILIM/ICOS monoclonal antibody
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selectively attenuated chronic GVHD (7). Other investiga-
tors have also shown that administration of CTLA-4Ig re-
sults in the suppression of both Th1- and Th2-mediated
immune responses, whereas ICOS-Ig treatment preferen-
tially suppresses only Th2-mediated immune response (5,
8). These results are consistent with the idea that CD28-
mediated costimulation is critically important for the initial
activation and proliferation of antigen-specific T cells,
whereas ICOS plays a role in the functional differentiation
and effector function of T cells. This functional difference
between CD28- and ICOS-mediated costimulation ap-
pears to be caused by their different cytokine production
capability. Although both CD28- and ICOS-mediated co-
stimulation affect the majority of cytokines produced, the
ICOS-mediated signal does not enhance IL-2 production.
Therefore, identification of the difference between these
two costimulatory signal transduction mechanisms in cy-
tokine production is of critical importance.
ICOS contains several conserved motifs also found in
CD28, including the YxxM motif in the cytoplasmic tail,
which binds the lipid kinase phosphatidylinositol 3-kinase
(PI3K) upon tyrosine phosphorylation after the ICOS liga-
tion (8). In the case of CD28, this motif is YMNM, which
also possesses the Grb2 binding motif, YxNx. However,
ICOS’s motif is YMFM, which does not contain the Grb2
binding motif. Using CD28 YMNM point and deletion
mutants, we have shown previously that mutation of Y in
this motif of CD28(YMNM) to F (Y189F mutant) did re-
duce, although maintained significant activity for IL-2 pro-
moter activation. However, the N191A mutant, which
retained PI3K binding ability and lost Grb2 binding,
completely lost all IL-2 promoter activity (12). Based on
these findings, we postulated that the reason why ICOS
does not have the ability to induce IL-2 production is be-
cause it fails to recruit Grb2. To verify this hypothesis, we
generated a mutant ICOS gene that contains the YMNM
motif by mutating Phe to Asn within the YMFM motif
and tested IL-2 promoter activation. The results indicated
that this single mutation in ICOS dramatically alters IL-2
promoter activity. These observations lead us to believe
that the difference of one amino acid, which alters Grb2
binding ability, may define a functional difference between
the CD28- and ICOS-mediated costimulatory signals.
 
Materials and Methods
 
Recombinant DNA Constructs.
 
Murine CD28 cDNA was pro-
vided by K. Lee (University of Miami School of Medicine, Miami,
FL). Mutant ICOS constructs were generated by oligonucleotide-
directed site-specific mutagenesis and verified by DNA sequencing.
For ICOS-CD28 chimeric construct, the extracellular and trans-
membrane domains of ICOS were fused to the cytoplasmic domain
of CD28 by PCR with overlapping primers. ICOS wild-type, mu-
tant, and ICOS-CD28 chimeric constructs were subcloned into the
mammalian expression vector pcDNA3.1/Zeo (Invitrogen). The
CD28RE/AP-1-luciferase reporter was obtained from A. Weiss
(University of California, San Francisco, San Francisco, CA). The
IL-2–, NFAT/AP-1–, and NF-
 
 
 
B–luciferase reporters were ob-
tained from K. Arai (University of Tokyo, Tokyo, Japan).
 
Transfections.
 
Jurkat-TAg cells were maintained in RPMI
1640 supplemented with 10% FCS, penicillin, streptomycin, 10
mM Hepes, pH 7.55, and 50 
 
 
 
M 2-ME. For transient transfec-
tions, exponentially growing cells were harvested, washed in
PBS, and resuspended at 4 
 
 
 
 10
 
7
 
 cells/ml. 10
 
7
 
 cells (0.25 ml)
were combined with 10 
 
 
 
g of effector construct and 5 
 
 
 
g of the
luciferase reporter gene in a 4-mm cuvette and electroporated
with a Gene Pulser (Bio-Rad Laboratories) at 240 V and 950 
 
 
 
F.
 
Promoter Activity Assay.
 
Jurkat-TAg cells were transiently
transfected with effector and reporter constructs. After 24 h, cells
were treated with 5 ng/ml PMA (LC Services Corp.) and 5 
 
 
 
g/ml
anti–mouse CD28 mAb PV-1 (13) or 5 
 
 
 
g/ml anti–mouse ICOS
mAb B10.5 (14), or 5 ng/ml PMA and 200 ng/ml ionomycin
(Sigma-Aldrich), with or without anti-ICOS antibody. After 8 h,
cell lysates were analyzed for luciferase activity with a luciferase
assay kit (Promega). In brief, cells were resuspended in 100 
 
 
 
l of
lysis buffer and incubated at room temperature for 15 min. After a
brief centrifugation, 50 
 
 
 
l of the supernatant was used with 100 
 
 
 
l
of luciferase assay reagent. Luminescence was measured immedi-
ately with a Lumat LB9501 (Berthold, Australia).
 
GST Fusion Proteins.
 
The cDNA encoding the cytoplasmic
domain of CD28 or ICOS was amplified by PCR and cloned
into the pGEX 4T-1 vector (Amersham Biosciences). Nonphos-
phorylated GST-CD28 was expressed in the 
 
Escherichia coli
 
BL21(DE3) pLysS strain (Novagen). Phosphorylated GST-ICOS
and GST-CD28 were expressed 
 
E. coli
 
 TKB1 strain (Stratagene),
a BL21(DE3) derivative strain that harbors a plasmid-encoded, in-
ducible tyrosine kinase gene. Bacterial cultures were grown to log
phase, induced by 0.3 mM isopropyl-1-thio-
 
 
 
-
 
d
 
-galactopyrano-
side, and incubated for 3 h at 37
 
 
 
C. The bacteria were lysed, and
purified on glutathione-Sepharose beads (Amersham Biosciences).
 
GST Precipitation and Western Immunoblots.
 
Jurkat cells were
lysed in the lysis buffer (1% NP-40, 20 mM Tris, pH 7.5, 150 mM
NaCl, 5 mM EDTA, 10 
 
 
 
g/ml leupeptin, 10 
 
 
 
g/ml aprotinin, 1
mM Na
 
3
 
VO
 
4
 
, and 50 mM NaF). The lysate was centrifuged at
20,000 
 
g
 
 for 10 min, and the supernatant was incubated with im-
mobilized GST fusion proteins on glutathione beads for 2 h at 4
 
 
 
C.
The beads were washed three times with lysis buffer and boiled in
the presence of the SDS sample buffer. The protein complexes
were resolved by 12% SDS-PAGE and transferred to polyvi-
nylidene difluoride membranes, and immunoblotted with antise-
rum specific for the p85 subunit of PI3-K (Upstate Biotechnology)
or anti–Grb2 antibody (C-23; Santa Cruz Biotechnology, Inc.).
 
Results
 
Mutating Phe to Asn of the YMFM Motif Provides ICOS
with the Ability to Induce IL-2 Promoter Activation.
 
We have
shown previously that the YMNM motif, which binds to
PI3-K and Grb2, is critical for IL-2 production and a single
alteration of Y to F attenuated the normal in vivo expan-
sion of alloreactive T cells in acute GVHD (15). ICOS pos-
sesses the YMFM motif in the corresponding region of the
CD28 YMNM motif, that binds to PI3-K but does not
bind Grb2 (8). We postulate that ICOS does not have the
ability to induce IL-2 production because it fails to recruit
Grb2. To verify this hypothesis, we generated a mutant
ICOS gene that has the YMNM motif instead, owing to a
mutation of F to N within the YMFM motif (Fig. 1 A). To
examine the effect of this mutation within the ICOS
YMFM motif on PI3-K or Grb2 association, we generatedT
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
259
 
Harada et al. Brief Definitive Report
 
a GST fusion protein of WT and each mutant of ICOS,
and tested their binding capability to PI3-K or Grb2 with
Jurkat lysates. As shown in Fig. 1 (B and C) ICOS WT was
found to associate with PI3-K, but not Grb2, in a phos-
phorylation-dependent manner. Tyr181 within the
YMFM motif was required for this association as the ICOS
Y181F mutant could not bind PI3-K. Conversely, the
ICOS YMNM mutant had a binding ability for both PI3-K
and Grb2 comparable to that of CD28. To examine the
effect of a single amino acid alteration of the YMFM motif
in ICOS-mediated IL-2 promoter activation, we cotrans-
fected ICOS WT and mutant genes with the IL-2–lucif-
erase reporter gene into Jurkat cells. We measured IL-2
promoter activation after ICOS ligation in these cells ex-
pressing the ICOS WT and YMNM mutant. It was found
that although ICOS WT failed to induce IL-2 promoter
activation by treatment with an anti-ICOS antibody in the
presence of PMA or PMA plus ionomycin, ICOS YMNM
mutant showed significant activity for IL-2 promoter acti-
vation under these conditions (Fig. 1 D).
To examine whether this one amino acid mutation in
the YMFM motif of ICOS is sufficient to induce IL-2 pro-
moter activation comparable to that of CD28, we created a
chimeric gene that contained the extracellular and trans-
membrane portions of ICOS and fused this to the cytoplas-
mic region of CD28 (Fig. 1 A). Jurkat cells were trans-
fected with ICOS WT, YMNM, or ICOS-CD28 chimera
together with an IL-2 reporter plasmid and tested for IL-2
promoter activation by stimulation with anti-ICOS anti-
body. Although the ICOS YMNM mutant induced sub-
stantial activation of IL-2 promoter compared with ICOS
WT, the ICOS-CD28 chimera had about a twofold higher
activity than ICOS YMNM. This result indicates that the
mutation of one amino acid in the YMFM motif of ICOS
is insufficient to fully restore IL-2 promoter activation to
the levels of CD28, whereas the CD28 cytoplasmic region
outside of the YMNM motif is essential for full activation.
 
Grb2 Binding to ICOS Was Sufficient to Activate the
NFAT/AP-1 Site in the IL-2 Promoter but Not the
CD28RE/AP-1 and NF-
 
 
 
B Sites.
 
The enhancer binding
sites for NFAT/AP-1 and CD28RE/AP-1 have been
identified previously as critical domains controlling IL-2
transcription in T cells (16). Therefore, we also analyzed
the ability of ICOS YMNM to activate these elements.
Figure 1. Mutating Phe to Asn
at the   2position of the YMFM
motif provides ICOS with ability
to induce IL-2 promoter activation.
(A) Structure of ICOS mutants.
In the point mutant Y181F, tyro-
sine 181 of the YMFM motif is
replaced with a phenylalanine
residue. In the mutant YMNM,
phenylalanine 183 of the YMFM
motif is replaced with an asparagine
residue. ICOS-CD28 chimera
contains the extracellular and trans-
membrane portion of ICOS fused
to the cytoplasmic region of
CD28. (B) Unphosphorylated
( ) or phosphorylated ( ) GST-
ICOS cytoplasmic domains were
precipitated with glutathione-
Sepharose beads, separated by
12% SDS-PAGE, and stained
with Coomassie blue. Equal
amounts of each were used in
C. (C) Jurkat cell lysates were
incubated  with immobilized
GST, GST-ICOS, or GST-CD28.
Precipitates were subjected to SDS-
PAGE and immunoblotted with
anti-p85 antiserum (top) and anti-
Grb2 antibody (bottom). (D)
Mouse ICOS WT or YMNM
mutant were transiently cotrans-
fected with the IL-2–luciferase
reporter gene in Jurkat-TAg cells.
24 h after transfection, these cells
were treated with 5 ng/ml PMA
and 5  g/ml anti-ICOS antibody
or 5 ng/ml PMA and 200 ng/ml
ionomycin, or PMA, ionomycin and anti-ICOS antibody. 8 h later, cells were lysed and luciferase activity in the cell lysate was measured. (E) Mouse
ICOS-WT, -YMNM mutant, or -CD28 chimera was transiently cotransfected with the IL-2–luciferase reporter gene in Jurkat-TAg cells. 24 h after
transfection, these cells were treated with 5 ng/ml PMA and 5  g/ml anti-ICOS antibody. 8 h later, cells were lysed and luciferase activity in the cell
lysate was measured. Each of the results shown is representative of at least three experiments.T
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Jurkat cells were transfected with ICOS WT, YMNM, or
ICOS-CD28 chimera together with the NFAT/AP-1 or
CD28RE/AP-1 reporter plasmid, and promoter activation
by PMA plus anti-ICOS antibody was measured. As shown
in Fig. 2 (A and B), ICOS-CD28 chimera, but not ICOS
WT, induced marked activation of the NFAT/AP-1 and
CD28RE/AP-1 reporters. Interestingly, it was found that
the ICOS YMNM mutant induced strong activity of the
NFAT/AP-1 reporter, comparable to that of the ICOS-
CD28 chimera, whereas it induced very weak activity in
the CD28RE/AP-1 reporter. Because the CD28RE/AP-1
element contains binding sites for both AP-1 and NF-
 
 
 
B
(17–19), we considered that the ICOS YMNM mutant
may not have the ability to activate NF-
 
 
 
B. To this end,
we tested whether the ICOS YMNM mutant was capable
of inducing NF-
 
 
 
B activation. It was found that although
ICOS-CD28 chimera, but not ICOS WT, induced signifi-
cant activation of the NF-
 
 
 
B reporter by ICOS ligation,
the ICOS YMNM mutant instead showed very weak ac-
tivity (Fig. 2 C). These results suggest that Grb2 binding to
ICOS may be sufficient to induce the activation of the
NFAT/AP-1 site within the IL-2 promoter and that the
reduced ability of the ICOS YMNM mutant for IL-2 pro-
moter activation may be due to its impaired activating ca-
pability for the CD28RE/AP-1 and NF-
 
 
 
B sites.
 
Discussion
 
Although cross-linking of both CD28 and ICOS can en-
hance T cell proliferation and cytokine production, ICOS-
mediated costimulation does not induce IL-2 production
(3–5). This difference between CD28 and ICOS costimu-
lation seems to reflect their main functions in T cell re-
sponses; i.e., CD28 signaling supports expansion of naive T
cells and ICOS induces T cell effector function. Therefore,
identification of the molecular mechanism responsible for
the difference in their capacity for IL-2 production is im-
portant to understand the nature of these two prominent
costimulatory signals. 
Using CD28 YMNM point and deletion mutants, we
have shown previously that mutation of Y in this motif of
CD28 reduced but left intact significant activity for IL-2
promoter activation. In contrast, the N191A mutant, which
retains PI3K binding but loses Grb2 binding, lost all IL-2
promoter activity (12). These findings prompted us to hy-
pothesize that ICOS cannot induce IL-2 production be-
cause it possesses the Grb2 nonbinding YMFM motif in-
stead of the YMNM motif. In fact, we found that the ICOS
mutant, whose PI3-K binding motif, YMFM, was replaced
by the YMNM used in CD28, showed a significant ability
for IL-2 promoter activation. This result suggested that the
difference of one amino acid in the cytoplasmic domain of
CD28 and ICOS may determine this functional difference
in T cell costimulation. However, it was found that Grb2
binding was insufficient for IL-2 promoter activation to lev-
els comparable to that produced by CD28. Because CD28
costimulation contributes to the activation of the IL-2 pro-
moter by up-regulating the activity of several transcription
factors (20–22), we used reporter constructs that contained
the NFAT/AP-1, CD28RE/AP-1, or NF-
 
 
 
B site to dis-
cern the effect of Grb2 binding to ICOS. The result showed
that the ICOS YMNM mutant induced strong activation of
the NFAT/AP-1 reporter comparable to that of CD28,
whereas it induced weak activation of the CD28RE/AP-1
and NF-
 
 
 
B sites. These results suggest that Grb2 binding to
ICOS may activate NFAT and AP-1 transcription factors
but not NF-
 
 
 
B family members. Then, in the CD28 cyto-
plasmic domain, which region is specifically involved in the
signaling pathway(s) required for NF-
 
 
 
B activation? In the
CD28 cytoplasmic domain outside of the YMNM motif,
three tyrosines exist that potentially bind to the SH2 do-
main and two PxxP motifs that potentially bind to the SH3
Figure 2. The ICOS YMNM mutant induced strong activation of the NFAT/AP-1 reporter, whereas it induced weak activation of CD28RE/AP-1 and
NF- B sites. Mouse ICOS-WT, -YMNM mutant, or -CD28 chimera was transiently cotransfected with the NFAT/AP-1 reporter (A), CD28RE/AP-1
reporter (B), or NF- B reporter gene (C) in Jurkat TAg cells. 24 h after transfection, these cells were treated with 5 ng/ml PMA and 5  g/ml anti-ICOS anti-
body. 8 h later, cells were lysed and luciferase activity in the cell lysate was measured. Each of the results shown is representative of at least three experiments.T
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domain. As several groups have reported that these amino
acids play a critical role in CD28-mediated costimulation
(23–25), it is conceivable that the regions containing these
amino acids may be involved in the activation of the
CD28RE/AP-1 and NF-
 
 
 
B sites. To determine which re-
gion is required for activation of NF-
 
 
 
B site, we transfected
various CD28 deletion mutants into Jurkat cells. The result
revealed that a CD28 deletion mutant lacking the COOH-
terminal PxxP motif showed a reduced ability to activate
the NF-
 
 
 
B site (unpublished data). It is reported that the
COOH-terminal PxxP motif is critical for T cell prolifera-
tion and cytokine production by CD28 costimulation (24,
25). Our result was consistent with these reports. As the
PxxP motif is not conserved in ICOS, this motif may be an-
other determinant that exemplifies a further difference be-
tween CD28 and ICOS. 
Although engagement of ICOS fails to enhance IL-2
production, it elicits multiple effects such as T cell prolifer-
ation and IL-4 and IFN-
 
 
 
 production. However, the intra-
cellular signaling pathways required for these events remain
to be defined. ICOS contains several conserved motifs
found in CD28, including the PI3-K binding motif in its
cytoplasmic domain. Through its lipid products, PI3-K is
involved in many cellular responses including proliferation,
survival, adhesion, and actin rearrangement. Some of these
cellular responses have been shown to be mediated by Akt.
For example, it is reported that PI3-K plays a critical role in
cell survival by activating Akt, which blocks apoptosis
through phosphorylation and inactivation of Bad, caspase-9,
and Forkhead family members (26). Furthermore, Brennan
et al. showed that PI3-K mediated activation of Akt stimu-
lates the activity of the cell cycle regulator E2F transcrip-
tion factors (27). Based on this information, it is conceiv-
able that ICOS signaling may be involved in cell survival
and cell cycle progression via the PI3-K-Akt pathway. In
the previous report, we showed that Grb2 has a stimulatory
role, whereas PI3-K has an inhibitory role in CD28-medi-
ated IL-2 promoter activation (12). It is likely that PI3K ac-
tivation induced by ICOS cross-linking also suppresses IL-2
promoter activation. If so, ICOS may not have an ability to
induce IL-2 production because it not only fails to recruit
Grb2, but also binds PI3-K.
Recently, Arimura et al. reported that the cross-link-
ing of ICOS induced much less phosphorylation of p46
JNK than did the cross-linking of CD28. However, they
found no difference in the phosphorylation of p38 and
ERK in signaling by ICOS and CD28 (28). Because ac-
tivation of JNK requires simultaneous stimulation of
CD3 and CD28, and likely plays an important role in
IL-2 production (29), weak activation of JNK induced
by cross-linking of ICOS may be responsible for its in-
effective costimulation for IL-2 production. Different
patterns of cytokine production between ICOS- and
CD28-mediated costimulation are also a matter of great
interest. It was reported that an inhibitor of p38 blocked
human CD4
 
 
 
 T cell production of IL-4, IL-5, TNF-
 
 
 
,
and IFN-
 
 
 
, but not IL-2, in response to CD3 and CD28
stimulation (30). Differential activation of MAPK family
 
members by CD28 and ICOS may also contribute to
their different cytokine production patterns.
In this paper, we revealed that Grb2 binding unique to
CD28 may define a difference in IL-2–inducing ability be-
tween CD28- and ICOS-mediated costimulation. The
identification of common or unique signaling pathways used
in CD28- and ICOS-mediated costimulation will contrib-
ute to further understand their individual roles in the regula-
tion of lymphocyte homeostasis and immune responses.
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